0001193125-24-100968.txt : 20240418 0001193125-24-100968.hdr.sgml : 20240418 20240418173007 ACCESSION NUMBER: 0001193125-24-100968 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 18 CONFORMED PERIOD OF REPORT: 20240412 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Termination of a Material Definitive Agreement ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240418 DATE AS OF CHANGE: 20240418 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDICAL PROPERTIES TRUST INC CENTRAL INDEX KEY: 0001287865 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32559 FILM NUMBER: 24855140 BUSINESS ADDRESS: STREET 1: 1000 URBAN CENTER DRIVE STREET 2: SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 BUSINESS PHONE: 205-969-3755 MAIL ADDRESS: STREET 1: 1000 URBAN CENTER DRIVE STREET 2: SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MPT Operating Partnership, L.P. CENTRAL INDEX KEY: 0001524607 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] ORGANIZATION NAME: 05 Real Estate & Construction IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-177186 FILM NUMBER: 24855141 BUSINESS ADDRESS: STREET 1: MEDICAL PROPERTIES TRUST, INC. STREET 2: 1000 URBAN CENTER DRIVE, SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 BUSINESS PHONE: 205-969-3755 MAIL ADDRESS: STREET 1: MEDICAL PROPERTIES TRUST, INC. STREET 2: 1000 URBAN CENTER DRIVE, SUITE 501 CITY: BIRMINGHAM STATE: AL ZIP: 35242 8-K 1 d804873d8k.htm 8-K 8-K
MEDICAL PROPERTIES TRUST INCfalse00012878650001524607ALAL 0001287865 2024-04-12 2024-04-12 0001287865 mpw:MptOperatingPartnershipLpMember 2024-04-12 2024-04-12
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM
8-K
 
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): April 12, 2024
 
 
MEDICAL PROPERTIES TRUST, INC.
MPT OPERATING PARTNERSHIP, L.P.
(Exact Name of Registrant as Specified in Charter)
 
 
Commission File Number
001-32559
Commission File Number
333-177186
 
Maryland
  
20-0191742
Delaware
  
20-0242069
(State or other jurisdiction of
incorporation or organization)
  
(I.R.S. Employer
Identification No.)
 
1000 Urban Center Drive, Suite 501
Birmingham,
AL
  
35242
(Address of principal executive offices)
  
(Zip Code)
Registrant’s telephone number, including area code: (205)
969-3755
 
 
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
 
☐
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
 
☐
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol
  
Name of each exchange
on which registered
Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc.   MPW   The New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
Item 1.01. Entry into a Material Definitive Agreement.
On April 12, 2024, Medical Properties Trust, Inc., a Maryland corporation (the “Company”), and MPT Operating Partnership, L.P., a Delaware limited partnership and the Company’s operating partnership (the “Operating Partnership” or the “Borrower”), entered into (i) Amendment No. 1 (the “Credit Facility Amendment”) to the Second Amended and Restated Revolving Credit and Term Loan Agreement, dated as of June 29, 2022, by and among the Company, the Borrower, JPMorgan Chase Bank, N.A., as administrative agent and the lenders party thereto (the “Credit Facility”), and (ii) the Fifth Amendment (the “Australia Facility Amendment”) to the Syndicated Facility Agreement, dated as of May 23, 2019, by and among the Company, the Borrower, Evolution Trustees Limited, as trustee for MPT Australia Realty Trust, Bank of America, N.A. as administrative agent and the lenders party thereto (the “Australia Facility”).
Also on April 12, 2024, the Company sold its interest in five Utah hospitals to a newly formed joint venture, generating immediate cash proceeds of approximately $1.1 billion (see Item 2.01 below). Because the Company has substantial liquidity and its foreseeable acquisition activities are significantly lower than in recent years, it no longer needs a $1.8 billion revolving credit capacity. Accordingly, the Credit Facility Amendment and the Australia Facility Amendment amend the Credit Facility and the Australia Facility, respectively, to (i) reduce revolving commitments from $1.8 billion to $1.4 billion, (ii) apply certain proceeds from the Utah and other asset sales and debt transactions (see subparagraph (iv)) to repay the Australia Facility and certain other outstanding obligations of the Borrower, including revolving loans under the Credit Facility to the extent necessary to reduce the outstanding borrowings to no more than the amended $1.4 billion commitment, (iii) lower the maximum permitted secured leverage ratio from 40% to 25%, and (iv) waive the 10% cap on unencumbered asset value attributable to tenants subject to a bankruptcy event for purposes of determining compliance with the unsecured leverage ratio for the trailing four fiscal quarter period ended June 30, 2024 and for purposes of determining pro forma compliance with the unsecured leverage ratio for certain asset sale and debt transactions.
Item 1.02 Termination of a Material Definitive Agreement.
On April 18, 2024, the Borrower repaid in full all outstanding obligations under the Australia Facility. All of the Company’s and its subsidiaries’ obligations under the Australia Facility have been paid and all commitments have been terminated. The Company and its subsidiaries did not incur any early termination penalties in connection with repayment of the indebtedness or termination.
Item 2.01 Completion of Acquisition or Disposition of Assets.
On April 12, 2024, affiliates of the Company and the Operating Partnership sold their interests in five Utah hospitals to a newly formed joint venture (the “Venture”) with Blue Owl RE Nucleus Holdco LLC (the “Fund”). The Company has retained an approximate 25% interest in the Venture with an aggregate agreed valuation of approximately $1.2 billion, and the Fund purchased an approximate 75% interest in the Venture for $886 million. There are no material relationships, other than in respect of the Venture, between the Company, the Operating Partnership, and the Fund or any of their affiliates.
Simultaneous with the closing of this sale transaction, the Venture placed new
non-recourse
secured financing that provided $190 million of additional cash to the Company based on its share of the proceeds.
Together, the two transactions delivered approximately $1.1 billion of cash proceeds to the Company.
As previously reported, the Utah lessee (an affiliate of CommonSpirit Health) may acquire the leased real estate at a price equal to the greater of fair market value and the approximate $1.2 billion lease base at the fifth or tenth anniversary of the 2023 master lease commencement. The Company granted certain limited and conditional preferences to the Fund based on the possible exercise of the lessee’s purchase option.
Item 7.01 Regulation FD Disclosure.
On April 12, 2024, we issued a press release announcing closing of the transactions described above in Item 2.01 of this Current Report on Form
8-K. A
copy of the press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
The information in Item 7.01 of this Current Report on Form
8-K,
including the information set forth in Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference in any filing of the Company or the Operating Partnership with the Securities and Exchange Commission, except as expressly set forth by specific reference in any such filing.
Item 9.01. Financial Statements and Exhibits.
 
(b)
Pro Forma Financial Information.
The unaudited pro forma condensed consolidated financial statements of the Company and the Operating Partnership as of December 31, 2023, and for the year ended December 31, 2023, are attached as Exhibit 99.2 hereto and are incorporated by reference herein.
(d)
Exhibits
.
 
Exhibit Number
   
Description
99.1    Press release dated April 12, 2024
99.2    Medical Properties Trust, Inc. and Subsidiaries and MPT Operating Partnership, L.P. and Subsidiaries unaudited pro forma condensed consolidated financial statements
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
2
SIGNATURES
Pursuant to the requirements of the Exchange Act, the registrants have duly caused this report to be signed on their behalf by the undersigned hereunder duly authorized.
 
MEDICAL PROPERTIES TRUST, INC.
By:  
/s/ R. Steven Hamner
Name:   R. Steven Hamner
Title:   Executive Vice President and Chief Financial Officer
Date: April 18, 2024
 
MPT OPERATING PARTNERSHIP, L.P.
By:  
/s/ R. Steven Hamner
Name:   R. Steven Hamner
Title:   Executive Vice President and Chief Financial Officer of the sole member of the general partner of MPT Operating Partnership, L.P.
Date: April 18, 2024
 
3
EX-99.1 2 d804873dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

 

   

Contact: Drew Babin, CFA, CMA

Senior Managing Director of Corporate Communications

Medical Properties Trust, Inc.

(646) 884-9809

dbabin@medicalpropertiestrust.com

MEDICAL PROPERTIES TRUST SELLS MAJORITY INTEREST IN UTAH HOSPITALS

Generates Approximately $1.1 Billion of Total Cash Proceeds to MPT

Brings Total Liquidity Transactions Year-to-Date to $1.6 Billion, or 80% of MPT’s Initial FY 2024 Target

Birmingham, AL – April 12, 2024 – Medical Properties Trust, Inc. (the “Company” or “MPT”) (NYSE: MPW) today announced that it has sold its interests in five Utah hospitals to a newly formed joint venture (the “Venture”) with an investment fund (the “Fund”) affiliated with a leading multi-strategy, multi-billion dollar institutional asset manager with a proven track record in real estate investments. MPT has retained an approximate 25% interest in the Venture and the Fund purchased an approximate 75% interest for $886 million, fully validating MPT’s underwritten lease base of approximately $1.2 billion. Simultaneous with the closing of this sale transaction, the Venture placed new non-recourse secured financing, providing $190 million of additional cash to MPT based on its share of the proceeds and further confirming underwritten asset values.

Together, the two transactions delivered approximately $1.1 billion of immediate cash proceeds to MPT, before costs and reserves. The proceeds are expected to be used to reduce outstanding debt – including payment in full of the approximate $300 million Australian term loan due 2024 and repayment of borrowings under its revolving credit facility – and for general corporate purposes.

Edward K. Aldag, Jr., Chairman, President and Chief Executive Officer said, “MPT’s approach to underwriting hospital real estate has once again been validated by highly sophisticated third-party participants in a broadening private market for real hospital assets. Our primary focus remains on accelerating our capital allocation strategy, and we are now confident that we will exceed our initial target of $2.0 billion in liquidity transactions in 2024 based on the valuations achieved on recent transactions and the terms we are actively negotiating for additional transactions.”

As previously reported, the Utah lessee (an affiliate of CommonSpirit Health) may acquire the leased real estate at a price equal to the greater of fair market value and the approximate $1.2 billion lease base at the fifth or tenth anniversary of the 2023 master lease commencement. MPT granted certain limited and conditional preferences to the Fund based on the possible exercise price of the lessee’s purchase option.

Eastdil Secured, L.L.C. acted as exclusive financial adviser, and Goodwin Procter LLP and Baker Donelson PC acted as legal advisers for MPT.

 

1

About Medical Properties Trust, Inc.

Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world’s largest owners of hospital real estate with 439 facilities and approximately 43,000 licensed beds in nine countries and across three continents as of December 31, 2023. MPT’s financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations. For more information, please visit the Company’s website at www.medicalpropertiestrust.com.

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can generally be identified by the use of forward-looking words such as “may”, “will”, “would”, “could”, “expect”, “intend”, “plan”, “estimate”, “target”, “anticipate”, “believe”, “objectives”, “outlook”, “guidance” or other similar words, and include statements regarding our strategies, objectives, future expansion and development activities, asset sales and other liquidity transactions, expected returns on investments and expected financial performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results or future events to differ materially from those expressed in or underlying such forward-looking statements, including, but not limited to: (i) macroeconomic conditions, including due to geopolitical conditions and instability, which may lead to a disruption of or lack of access to the capital markets, disruptions and instability in the banking and financial services industries, rising inflation and movements in currency exchange rates; (ii) the risk that MPT is not able to recover deferred rent or its other investments in Steward at full value, within a reasonable time period or at all; (iii) the risk that previously announced or contemplated property sales, loan repayments, and other capital recycling transactions do not occur as anticipated or at all; (iv) the risk that MPT is not able to attain its leverage, liquidity and cost of capital objectives within a reasonable time period or at all; (v) MPT’s ability to obtain debt financing on attractive terms or at all, as a result of changes in interest rates and other factors, which may adversely impact its ability to pay down, refinance, restructure or extend its indebtedness as it becomes due, or pursue acquisition and development opportunities; (vi) the ability of our tenants, operators and borrowers to satisfy their obligations under their respective contractual arrangements with us; (vii) the economic, political and social impact of, and uncertainty relating to, the potential impact from health crises (like COVID-19), which may adversely affect MPT’s and its tenants’ business, financial condition, results of operations and liquidity; (viii) our success in implementing our business strategy and our ability to identify, underwrite, finance, consummate and integrate acquisitions and investments; (ix) the nature and extent of our current and future competition; (x) international, national and local economic, real estate and other market conditions, which may negatively impact, among other things, the financial condition of our tenants, lenders and institutions that hold our cash balances, and may expose us to increased risks of default by these parties; (xi) factors affecting the real estate industry generally or the healthcare real estate industry in particular; (xii) our ability to maintain our status as a REIT for income tax purposes in the U.S. and U.K.; (xiii) federal and state healthcare and other regulatory requirements, as well as those in the foreign jurisdictions where we own properties; (xiv) the value of our real estate assets, which may limit our ability to dispose of assets at attractive prices or obtain or maintain equity or debt financing secured by our properties or on an unsecured basis; (xv) the ability of our tenants and operators to operate profitably and generate positive cash flow, remain solvent, comply with applicable laws, rules and regulations in the operation of our properties, to deliver high-quality services, to attract and retain qualified personnel and to attract patients; (xvi) potential environmental contingencies and other liabilities; (xvii) the risk that the expected sale of three Connecticut hospitals currently leased to Prospect does not occur; (xviii) the risk that MPT is unable to monetize its investment in Prospect Medical Holdings, Inc. at full value within a reasonable time period or at all; and (xix) the cooperation of our joint venture partners, including adverse developments affecting the financial health of such joint venture partners or the joint venture itself; and (xx) the risks and uncertainties of litigation or other regulatory proceedings.

 

2

The risks described above are not exhaustive and additional factors could adversely affect our business and financial performance, including the risk factors discussed under the section captioned “Risk Factors” in our most recent Annual Report on Form 10-K, as may be updated in our other filings with the SEC. Forward-looking statements are inherently uncertain and actual performance or outcomes may vary materially from any forward-looking statements and the assumptions on which those statements are based. Readers are cautioned to not place undue reliance on forward-looking statements as predictions of future events. We disclaim any responsibility to update such forward-looking statements, which speak only as of the date on which they were made.

# # #

 

3

EX-99.2 3 d804873dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

Joint Venture Transaction

These unaudited pro forma condensed consolidated financial statements of Medical Properties Trust, Inc. and subsidiaries, and of MPT Operating Partnership, L.P. and subsidiaries have been prepared to give pro forma effect to the joint venture transaction described below:

On April 12, 2024, affiliates of Medical Properties Trust, Inc. (together with its consolidated subsidiaries, the “Company”) and MPT Operating Partnership, L.P. (together with its consolidated subsidiaries, the “Operating Partnership”) sold their interests in five Utah hospitals to a newly formed joint venture (the “Venture”) with Blue Owl RE Nucleus Holdco LLC (the “Fund”). The Company has retained an approximate 25% interest in the Venture with an aggregate agreed valuation of approximately $1.2 billion, and the Fund purchased an approximate 75% interest in the Venture for $886 million. There are no material relationships, other than in respect of the Venture, between the Company, the Operating Partnership, and the Fund or any of their affiliates.

Simultaneous with the closing of this sale transaction, the Venture placed new non-recourse secured financing that provided $190 million of additional cash to the Company based on its share of the proceeds.

Together, the two transactions delivered approximately $1.1 billion of cash proceeds to the Company.

As previously reported, the Utah lessee (an affiliate of CommonSpirit Health) may acquire the leased real estate at a price equal to the greater of fair market value and the approximate $1.2 billion lease base at the fifth or tenth anniversary of the 2023 master lease commencement. The Company granted certain limited and conditional preferences to the Fund based on the possible exercise price of the lessee’s purchase option.

We collectively refer to these transactions as the “Joint Venture Transactions”.

Basis of Presentation of the Unaudited Pro Forma Combined Financial Information

The unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Article 11 of Regulation S-X.

The historical consolidated financial statements have been adjusted in the unaudited pro forma condensed consolidated financial statements to give effect to pro forma events that are (1) directly attributable to the Joint Venture Transactions, (2) factually supportable and (3) with respect to the unaudited pro forma condensed consolidated statement of income (which we refer to as the pro forma statement of income), expected to have a continuing impact on our results. The pro forma statement of income for the year ended December 31, 2023, gives effect to the Joint Venture Transactions as if they occurred on January 1, 2023. The unaudited pro forma condensed consolidated balance sheet as of December 31, 2023, gives effect to the Joint Venture Transactions as if they each occurred on December 31, 2023.

The unaudited pro forma condensed consolidated financial statements were based on and should be read in conjunction with:

 

  •  

the accompanying notes to the unaudited pro forma condensed consolidated financial statements; and

 

  •  

the Company’s and Operating Partnership’s consolidated financial statements for the year ended December 31, 2023 and the notes relating thereto, which were prepared in accordance with U.S. Generally Accepted Accounting Principles, and are included in the Company’s and the Operating Partnership’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 29, 2024.

The unaudited pro forma condensed consolidated financial statements have been presented for informational purposes only and are not necessarily indicative of what our results of operations and financial position would have been had the Joint Venture Transactions been completed on the dates indicated. In addition, the pro forma financial statements do not purport to project our future results of operations or financial position.

The unaudited pro forma financial statements contain estimated adjustments, based on available information and certain assumptions that management believes are reasonable under the circumstances. The assumptions underlying the pro forma adjustments are further described in the accompanying notes to the unaudited pro forma condensed consolidated financial statements. These assumptions were based on preliminary information and estimates and are subject to changes as additional information becomes available. Actual results may differ materially from the amounts reflected in the unaudited pro forma condensed consolidated financial statements.

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Unaudited Pro Forma Condensed Consolidated Balance Sheet

 

     Medical
Properties Trust,
Inc. Historical
December 31, 2023		     Joint
Venture
Transactions
Pro Forma
Adjustments		          Medical
Properties Trust,
Inc.
Pro Forma
December 31, 2023		  
     (Amounts in thousands)  

Assets

          

Real estate assets

          

Land, buildings and improvements, intangible lease assets, and other

    $ 13,237,187     $ (887,973 )    (A)    $ 12,349,214  

Investment in financing leases

      1,231,630       —           1,231,630  

Mortgage loans

      309,315       —           309,315  
  

 

 

    

 

 

       

 

 

  

Gross investment in real estate assets

      14,778,132       (887,973 )         13,890,159  

Accumulated depreciation and amortization

      (1,407,971 )      101,787     (A)      (1,306,184 ) 
  

 

 

    

 

 

       

 

 

  

Net investment in real estate assets

      13,370,161       (786,186 )         12,583,975  

Cash and cash equivalents

      250,016       1,058,872     (B)      1,308,888  

Interest and rent receivables

      45,059       —           45,059  

Straight-line rent receivables

      635,987       (15,770 )    (A)      620,217  

Investments in unconsolidated real estate joint ventures

      1,474,455       107,595     (C)      1,582,050  

Investments in unconsolidated operating entities

      1,778,640       —           1,778,640  

Other loans

      292,615       —           292,615  

Other assets

      457,911       (550 )         457,361  
  

 

 

    

 

 

       

 

 

  

Total Assets

    $ 18,304,844     $ 363,961        $ 18,668,805  
  

 

 

    

 

 

       

 

 

  

Liabilities and Equity

          

Liabilities

          

Debt, net

    $ 10,064,236     $ —         $ 10,064,236  

Accounts payable and accrued expenses

      412,178       50,000     (D)      462,178  

Deferred revenue

      37,962       (8,047 )    (E)      29,915  

Obligations to tenants and other lease liabilities

      156,603       —           156,603  
  

 

 

    

 

 

       

 

 

  

Total Liabilities

      10,670,979       41,953          10,712,932  

Total Equity

      7,633,865       322,008     (F)      7,955,873  
  

 

 

    

 

 

       

 

 

  

Total Liabilities and Equity

    $ 18,304,844     $ 363,961        $ 18,668,805  
  

 

 

    

 

 

       

 

 

  

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

Unaudited Pro Forma Condensed Consolidated Statement of Income

 

     Medical
Properties Trust,
Inc. Historical For
the Year Ended
December 31, 2023		     Joint
Venture
Transactions
Pro Forma
Adjustments		         Medical
Properties Trust,
Inc. Pro Forma
For the Year
Ended
December 31, 2023		  
     (Amounts in thousands,
except for per share data)		  

Revenues

         

Rent billed

    $ 803,375     $ (98,562 )    (G)   $ 704,813  

Straight-line rent

      (127,894 )      71,581     (G)     (56,313 ) 

Income from financing leases

      127,141       —          127,141  

Interest and other income

      69,177       (10 )    (G)     69,167  
  

 

 

    

 

 

      

 

 

  

Total revenues

      871,799       (26,991 )        844,808  

Expenses

         

Interest

      411,171       —          411,171  

Real estate depreciation and amortization

      603,360       (311,969 )    (G)     291,391  

Property-related

      41,567       (168 )    (G)     41,399  

General and administrative

      145,588       —          145,588  
  

 

 

    

 

 

      

 

 

  

Total expenses

      1,201,686       (312,137 )        889,549  

Other expense

         

Loss on sale of real estate

      (1,815 )      —          (1,815 ) 

Real estate and other impairment charges, net

      (376,907 )      —          (376,907 ) 

Earnings from equity interests

      13,967       (86,780 )    (H)     (72,813 ) 

Debt refinancing and unutilized financing benefit

      285       —          285  

Other (including fair value adjustments on securities)

      7,586       —          7,586  
  

 

 

    

 

 

      

 

 

  

Total other expense

      (356,884 )      (86,780 )        (443,664 ) 
  

 

 

    

 

 

      

 

 

  

(Loss) income before income tax

      (686,771 )      198,366         (488,405 ) 

Income tax benefit

      130,679       —          130,679  
  

 

 

    

 

 

      

 

 

  

Net (loss) income

      (556,092 )      198,366         (357,726 ) 

Net income attributable to non-controlling interests

      (384 )      643     (G)     259  
  

 

 

    

 

 

      

 

 

  

Net (loss) income attributable to MPT common stockholders

    $ (556,476 )    $ 199,009       $ (357,467 ) 
  

 

 

    

 

 

      

 

 

  

Earnings per common share — basic and diluted

         

Net loss attributable to MPT common stockholders

    $ (0.93 )        $ (0.60 ) 
  

 

 

        

 

 

  

Weighted average shares outstanding — basic

      598,518           598,518  
  

 

 

        

 

 

  

Weighted average shares outstanding — diluted

      598,518           598,518  
  

 

 

        

 

 

  

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

Unaudited Pro Forma Condensed Consolidated Balance Sheet

 

     MPT Operating
Partnership L.P.
Historical
December 31,
2023		     Joint Venture
Transactions
Pro Forma
Adjustments		           MPT Operating
Partnership L.P.
Pro Forma
December 31, 2023		  

Assets

      (Amounts in thousands)  

Real estate assets

         

Land, buildings and improvements, intangible lease

assets, and other

    $ 13,237,187     $ (887,973 )      (A )    $ 12,349,214  

Investment in financing leases

      1,231,630       —          1,231,630  

Mortgage loans

      309,315       —          309,315  
  

 

 

    

 

 

      

 

 

  

Gross investment in real estate assets

      14,778,132       (887,973 )        13,890,159  

Accumulated depreciation and amortization

      (1,407,971 )      101,787       (A )      (1,306,184 ) 
  

 

 

    

 

 

      

 

 

  

Net investment in real estate assets

      13,370,161       (786,186 )        12,583,975  

Cash and cash equivalents

      250,016       1,058,872       (B )      1,308,888  

Interest and rent receivables

      45,059       —          45,059  

Straight-line rent receivables

      635,987       (15,770 )      (A )      620,217  

Investments in unconsolidated real estate joint ventures

      1,474,455       107,595       (C )      1,582,050  

Investments in unconsolidated operating entities

      1,778,640       —          1,778,640  

Other loans

      292,615       —          292,615  

Other assets

      457,911       (550 )        457,361  
  

 

 

    

 

 

      

 

 

  

Total Assets

    $ 18,304,844     $ 363,961       $ 18,668,805  
  

 

 

    

 

 

      

 

 

  

Liabilities and Equity

         

Liabilities

         

Debt, net

    $ 10,064,236     $ —        $ 10,064,236  

Accounts payable and accrued expenses

      318,980       50,000       (D )      368,980  

Deferred revenue

      37,962       (8,047 )      (E )      29,915  

Obligations to tenants and other lease liabilities

      156,603       —          156,603  

Payable due to Medical Properties Trust, Inc.

      92,808       —          92,808  
  

 

 

    

 

 

      

 

 

  

Total Liabilities

      10,670,589       41,953         10,712,542  

Total Capital

      7,634,255       322,008       (F )      7,956,263  
  

 

 

    

 

 

      

 

 

  

Total Liabilities and Capital

    $ 18,304,844     $ 363,961       $ 18,668,805  
  

 

 

    

 

 

      

 

 

  

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

Unaudited Pro Forma Condensed Consolidated Statement of Income

 

     MPT Operating
Partnership, L.P.
Historical For the
Year Ended
December 31,
2023		     Joint Venture
Transactions Pro
Forma
Adjustments		           MPT Operating
Partnership, L.P.
Pro Forma For
the Year Ended
December 31,
2023		  
     (Amounts in thousands,
except for per unit data)		  

Revenues

         

Rent billed

    $ 803,375     $ (98,562 )      (G )    $ 704,813  

Straight-line rent

      (127,894 )      71,581       (G )      (56,313 ) 

Income from financing leases

      127,141       —          127,141  

Interest and other income

      69,177       (10 )      (G )      69,167  
  

 

 

    

 

 

      

 

 

  

Total revenues

      871,799       (26,991 )        844,808  

Expenses

         

Interest

      411,171       —          411,171  

Real estate depreciation and amortization

      603,360       (311,969 )      (G )      291,391  

Property-related

      41,567       (168 )      (G )      41,399  

General and administrative

      145,588       —          145,588  
  

 

 

    

 

 

      

 

 

  

Total expenses

      1,201,686       (312,137 )        889,549  

Other expense

         

Loss on sale of real estate

      (1,815 )      —          (1,815 ) 

Real estate and other impairment charges, net

      (376,907 )      —          (376,907 ) 

Earnings from equity interests

      13,967       (86,780 )      (H )      (72,813 ) 

Debt refinancing and unutilized financing benefit

      285       —          285  

Other (including fair value adjustments on securities)

      7,586       —          7,586  
  

 

 

    

 

 

      

 

 

  

Total other expense

      (356,884 )      (86,780 )        (443,664 ) 
  

 

 

    

 

 

      

 

 

  

(Loss) income before income tax

      (686,771 )      198,366         (488,405 ) 

Income tax benefit

      130,679       —          130,679  
  

 

 

    

 

 

      

 

 

  

Net (loss) income

      (556,092 )      198,366         (357,726 ) 

Net income attributable to non-controlling interests

      (384 )      643       (G )      259  
  

 

 

    

 

 

      

 

 

  

Net (loss) income attributable to MPT Operating Partnership partners

    $ (556,476 )    $ 199,009       $ (357,467 ) 
  

 

 

    

 

 

      

 

 

  

Earnings per unit — basic and diluted

         

Net loss attributable to MPT Operating Partnership partners

    $ (0.93 )        $ (0.60 ) 
  

 

 

        

 

 

  

Weighted average units outstanding — basic

      598,518           598,518  
  

 

 

        

 

 

  

Weighted average units outstanding — diluted

      598,518           598,518  
  

 

 

        

 

 

  

The accompanying notes are an integral part of these unaudited pro forma condensed consolidated financial statements.

MEDICAL PROPERTIES TRUST, INC. AND SUBSIDIARIES

MPT OPERATING PARTNERSHIP, L.P. AND SUBSIDIARIES

Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements

 

(A)

Represents the assets contributed to the Venture.

 

(B)

Represents net cash proceeds from the Joint Venture Transactions (in millions):

 

Proceeds from Fund equity investment

    $ 886  

Proceeds from Venture’s secured financing arrangement

      192  

Transaction costs

      (19 ) 
  

 

 

  

Total net cash proceeds

    $ 1,059  
  

 

 

  

For pro forma purposes, all proceeds from the Joint Venture Transactions are reflected in cash; however, the Company has used some of the proceeds to fully prepay its Australian term loan due 2024 and expects to use the remaining proceeds to repay balances under its revolving credit facility and for general corporate purposes.

 

(C)

Represents the Company’s net equity investment in the Venture.

 

(D)

The Utah lessee (an affiliate of CommonSpirit Health) may acquire the leased real estate at a price equal to the greater of fair market value and the approximate $1.2 billion lease base at the fifth or tenth anniversary of the 2023 master lease commencement. The Company granted certain limited and conditional preferences to the Fund based on the possible exercise of the lessee’s purchase option. We have assumed these preferences will be accounted for as a derivative at fair value pursuant to ASC 815 “Derivatives and Hedging”. This balance represents our best estimate of the derivative’s fair value at this time, but such value is subject to change as we finalize our calculations.

 

(E)

Represents rent on assets contributed to the Venture that was prepaid by the Utah lessee.

 

(F)

Reflects an approximate $322 million net gain on the sale of the assets contributed to the Venture. This estimate is subject to change based on the finalization of the value of the derivative liability as described in footnote (D).

 

(G)

Removes 100% of the income statement impact from the assets contributed to the Venture as with this Joint Venture Transaction we will deconsolidate these assets and related income from our financial statements and report only our 25% share as discussed in footnote (H).

These pro forma adjustments include the impact from the May 1, 2023 transaction (as disclosed in our previous filings), in which an affiliate of CommonSpirit Health acquired the Utah hospital operations of the five facilities contributed to the Venture.

 

(H)

Reflects our estimate of the Company’s share of net income from the Venture under the equity method of accounting pursuant to ASC 323 “Investments – Equity Method and Joint Ventures”. We expect to account for our share of the income in this equity method investment on a quarter-lag basis.

Our share of the Venture’s income for 2023 for pro forma purposes includes the impact of the transaction described in footnote (G). Excluding the impact from the transaction described in footnote (G), the 2023 pro forma adjustments representing the Company’s share of net income from the Venture would be income of approximately $8 million.

EX-101.SCH 4 mpw-20240412.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 mpw-20240412_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 mpw-20240412_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 mpw-20240412_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 8 mpw-20240412_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 9 g804873g0419011500544.jpg GRAPHIC begin 644 g804873g0419011500544.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#KOB?XL\5^ M$+^VN-.DMCI=RNT&2#<8Y!U!.>XY'XUP/_"Z/&'_ #UL?_ ;_P"O7NWBGP_; M^)_#MWI5Q@>:N8WQRCCE6_ U\GWUE<:;?W%E=QF.XMY#'(OH14.Z..NYPE=/ M0[V3XQ>-8<>;]ECSTWVA7/YFKFF?%#QUJDF(6LQ&/O/]ES^0SS6K_92>*OA' MIK7'M;GB'ER_9'6';V51R1^)'Y M4]1+GNO>,NX^(/C:SDBD)BGM]P$@6Q.X#UX-))\2?%]UJGV.Q-N/*3=.6M"2 MN>G&:US<3K\+%=9Y%KD,!GUJYK-_P#8=$TO6$41ZK>6AA>51AFZ?,?? M_&@?O6OS'-7_ (_\>VT9DMS!.H^\OV([A^M8DGQD\9PR-'*UFDB'#*UM@@^A MYKM]2U6]L_"GAN[BN9!+OOK7*V7@^#QCXV,Z@QP23FXN0!P4SD_0 MGI0[DR<[VBSU3X?:CK^L>'$U/7FBWW)W01QQ;-L?8GZ_RKK*9%&D,211J$C1 M0JJ!P .@I]4=J5E8IS:KI]M.()[V"*4D (\@4G/UJY7$_$?3'U+3;5;= ;E' M:13CG"H20/RK5\%ZV-<\.03,V9XAY4OKD=_Q%.VEPOK8W+BY@M(6FN9HX8EZ MO(P 'XFBWNH+N/S+>5)4_O( '_#K3:$C>HJ.:>*W3?-( MD:^K-@4VWNK>[3?;3QS*."8V#?RI#)JYSQ+XGET%[9$L'E$\HC$K, @)_6MM MK^S2=8&NH5E8X"%QDGZ5R7Q'_P"//2O^OU*:W$]CM <@'UJG<:OIUI(8[F]M MX7'\,D@4_K5Q?NCZ5P/Q%1#?Z"2H)-T >/I0E<&['8P:SIMS,(8;Z!Y3T0.- MQ^@J]7$_$NS@_P"$;%ZJA+FVE4Q2+P171:->^9HFG27*1XSAU1P2OUJ%M5T])Q"U[ LA. ID')]*0RY13))HX8S) M+(B(.K,V /QJO/JFGVLB1W%[;Q._W5>0 F@"W12!@5W @KC.:KIJ%G+/Y$=W M"TO]P2 G\J +-%1M<0I+Y331B3;NV%AG'KCTJM+J^GQ6 M:7?(K."4/IQ0!O456FU"SMI D]U#&Q.,.X!J66XA@C\R65$3^\QP* )*JWNH MV>G(CWMS' CMM5I&P"?K4MO=6]W'YEM-',F<;D8$9JCJFCPZK=6+7"J\-M(9 M2C=&;&!_6@!YU[25QNU*T7(R,RJ,TTZ_I/GQP#4+.VY>*ZS5-(MKR6RNV2-);.82K(>,#!R,^E.R%=FK158ZA9CR< MW< \[_5?O!\_T]:F\Z(S&$2)YH&XIN&<>N*0Q]%,,T0F$)D02L-P3=R1ZXJ& M?4+*U<)<74,3'L[@4 6:*HW^KV.G"(7%Q&K2R+&B;ADEC@?AWS5J*XAG#&&6 M.3:<'8P./RH DKQ3XV>$MK1>)[2/@XBO H_!7_H?PKVNJVH6%OJFG7%C=QB2 MWGC,;J>X-)JY%2"G&QX1\/\ 5([#Q)I&EW!_T35M*^SR*>A8O(5_J/QK7\)Q MI8^)/$?A^.8RQ:?I#P;L_>??N8_7+8_"N%\92ZIHWB:"PN(8()=(VK9RPQ[2 MT0.Y#[_XYJAI7C#4]'O=0O8%@>XO]PN))4W%@QRP^A-3Q<;R2F<-USFLQ-3NO[:^R"+?"0N2!TR,YIDSE>R1T'Q!>4> O"84LK, MTN54]\]*].^&?A9O#?A>-KD'[?=@2S%NJC^%?P'ZFN,\&07?B_7([2^M[9]% MT-Q)#B/D2'D+GOSR:]GH7"_ M'UU8RG9I]\-\9/0'J/UR/QKL=0BU:37;*XMK>)K6WW;]TF&;(QQ]*@\3^%X_ M$36$C$(]O,&8^J?Q"J0F<_XOA:3P)TZ/* M6^IZ<%\IPV5;'_ZA0F)HMWOAB[O=OZU M?W>)&@F\B%6Y$:C/0>^*U],N/$4PCCO[*V@V\22K)NW?05C0Z'K/A[Q+=WFE M0Q75E>G=)$[[2C>M #([>&W^+6(8UC#V99@HQD\\U'J-K'!\4M*92Y\R)V;< MQ/-7/[#UQO&<6LE[94\CRW')V^P]?K4VH:/J=QXSL=6BBB-O;(48%\,V>XH MKZ%>MK?C35VN?FCL@(H(ST7U./6KZ^$X['^U9=+NI+:XOEP"3E8SZ@50N] U M72O$TNMZ(L4J7(Q<6TC;(M#UG5]/TV!4MS+;2K+(V[ ..PI@=@OW1]*X/XB?\ '_H' M_7T/Z5W41SCA$=I+YA,CXW5*W&]C3U/P^VM MS0KJ-SOM(GWBWC7 <]MQ[US7C:P@BUW07B#(TEQL8JQZ>@]*[R!Y7C!FB\M^ MZALUS/BG1=2U;4M,GLXXBEG+YC%WQN]J$P:,WQ=I]IX6T:]U#2HVM[F[*PNR ML< 'J1Z&MF[T6SO?!0M?*7 MMZ-CD,!G.:O:UI*^(-"FL;E?*:09&#G:PZ&L MS3X->M] ;29K:-IEC,4=R'^4KTR1USBF*QQ\D[:O\+9KB\+R7-F_EI(6/8UU MC>&=,U+PBGG6RF9K8.)CRX;;US5'Q#HT6@_#2YL8VW;0"[_WF)Y-:&G3:U<^ M&8;1;&..5X BSF3* $8SCKG':@#CK;7;X^#-,T_S2#/>FV:0GJ@(XS^E=?J? MA:[U.YTV=9K:U:R<,&A0Y9>..M1ZAX&BF\+6VF6LVRYM6\V.8]W[Y^M7]*G\ M2F..WOK.V0I@-<"3.X>H'K1?L"7]:?B;2YM< M\-W5C$0DTJC;N/&0M0ZU::QX=@T.[C5M1 MAT^-HYU ZY_BQ]*NZ%8^)O#L/]F+;V]Y9HQ\F8R;2H]"*V;D:S#?V]PD<5S MT6RXA#;<-G((S^5%]0L1^%K_ $K4[2XO=+7R_.DW31$8*/@ \?A6_6%X=T(: M3/J-R56-KV?S!$O2,=A6[28TA:KK6J:9/:10K'8R^9\\G+\@_TK?U2*[O=!NK>*%1<3Q- M&%9^!D$9S3[!W.6\*>&M,U;PII%U>1,\\6'23>01AC@?3VI^BVT=K\4-9BBS MM^RHV"<\G!-;?A.POM(T*WTZ]BC#0 @.CY#21G^59TVIG0=7U;3O$=DTNFZC.SI M=;9?&/PC_;&A#6;2/-[8 EPHY>+N/PZ_G7SW7V@Z+( MC(X#*PP0>A%?+?Q$\*-X4\4S01H18W&9K8]@I/*_@?TQ4R1Q8FG]M$>G7!LO M#OVF0M,N?E3TYQBM*UF?4;V;3X(V6O6OACHB7=U+K,D&V.%MD)*_?? ^;\ <4(RIQK)/X5N;6"*26:7 1$7)/-:F@3+)HUJFUT>.)5 M=77!!Q6G13Z"ZA1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %L32/!6F:-XIU/7 MK=?W]\!A,<1?W\?[QP:Z6DE8RHTN1:A1113-@HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH 4H **** "BBB@ HHHH **** /_]D! end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover Page
Apr. 12, 2024
Document Information [Line Items]  
Entity Registrant Name MEDICAL PROPERTIES TRUST INC
Amendment Flag false
Entity Central Index Key 0001287865
Document Type 8-K
Document Period End Date Apr. 12, 2024
Entity File Number 001-32559
Entity Incorporation State Country Code MD
Entity Tax Identification Number 20-0191742
Entity Address, Address Line One 1000 Urban Center Drive
Entity Address, Address Line Two Suite 501
Entity Address, City or Town Birmingham
Entity Address, State or Province AL
Entity Address, Postal Zip Code 35242
City Area Code 205
Local Phone Number 969-3755
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc.
Trading Symbol MPW
Security Exchange Name NYSE
Entity Emerging Growth Company false
MPT Operating Partnership LP [Member]  
Document Information [Line Items]  
Entity Registrant Name MPT OPERATING PARTNERSHIP, L.P.
Entity Central Index Key 0001524607
Entity File Number 333-177186
Entity Incorporation State Country Code DE
Entity Tax Identification Number 20-0242069
Entity Address, Address Line One 1000 Urban Center Drive
Entity Address, Address Line Two Suite 501
Entity Address, City or Town Birmingham
Entity Address, State or Province AL
Entity Address, Postal Zip Code 35242
City Area Code 205
Local Phone Number 969-3755
Entity Emerging Growth Company false
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 2 23 1 false 1 0 false 0 false false R1.htm 1001 - Document - Cover Page Sheet http://www.medicalpropertiestrust.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityRegistrantName - d804873d8k.htm 7 d804873d8k.htm mpw-20240412.xsd mpw-20240412_cal.xml mpw-20240412_def.xml mpw-20240412_lab.xml mpw-20240412_pre.xml http://xbrl.sec.gov/dei/2023 true true JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d804873d8k.htm": { "nsprefix": "mpw", "nsuri": "http://www.medicalpropertiestrust.com/20240412", "dts": { "inline": { "local": [ "d804873d8k.htm" ] }, "schema": { "local": [ "mpw-20240412.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "mpw-20240412_cal.xml" ] }, "definitionLink": { "local": [ "mpw-20240412_def.xml" ] }, "labelLink": { "local": [ "mpw-20240412_lab.xml" ] }, "presentationLink": { "local": [ "mpw-20240412_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 1, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 6 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 36 }, "report": { "R1": { "role": "http://www.medicalpropertiestrust.com/role/CoverPage", "longName": "1001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "P04_12_2024To04_12_2024", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d804873d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "P04_12_2024To04_12_2024", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d804873d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "mpw_MptOperatingPartnershipLpMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medicalpropertiestrust.com/20240412", "localname": "MptOperatingPartnershipLpMember", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "MPT Operating Partnership LP [Member]", "documentation": "MPT Operating Partnership LP." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.medicalpropertiestrust.com/role/CoverPage" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 20 0001193125-24-100968-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-100968-xbrl.zip M4$L#!!0 ( ,*+DE@$ZLL+&1@ !^3 . 9#@P-#@W,V0X:RYH=&WM M7>MSVLBR_[Y_Q12[.6M7\9+ -L:.3Q%,=GW6L5V8[.Z]7TX-T@"S$9)V)&PX M?_WM[M&3E\'!.#G7J4H"TCQZ>OKQZYX'Y_^5EZE2L<2&MY47B1+QCZ:D5)>),K.@E*0\[]I/2 !WWB8_0B5WCJK)FG/Z\S M4C8)U9KI@;<)J2I<[!L>YH5DNJHQ T4/Q%O\^:%[G18/EY=/BU9"Q=U@X*DQ M#T'UL3>S5#5+QG%6XM<-=UY;H=,2<#E7(^;ZNGZ-HU*U4:H943NKE1AM4 %M MD> V_!?*T!$7C=)OYQ7]\8?SL0@YLSPW%"XP(!33L(*5SI@UXBH0X?O/O8^E M1H%A#R7Q]T0^O"^T=?%2;^:+0@4:J43M]SU[QH)PYHCW!:2^-!)R. J;+M+N MG/6Y]66H0%_LDN4YGFH^CF0HS@H7Y[9\B.O9,O =/FLRUW,%O)+3)K8NE/XH M;5NX]!'>WTS&0DF+N7R,-85L=EP8V*PKAC) KH4W\*; ).H]U30,HUZM5AO5 M@A[T-.R*P?O"7;7^;\/\-QK?GI=^+EQ\ZEQ>M5O7[*Y[>]?I]JXZ]ZS7_7S? M8U M)+FG1?%IO/B0+EK7+T;]\8;"OX2$2EX'E1@(]&4BN#A'X]8," I LXP 1#,$ M$_&^$,BQ[Z#5HV '(;:ZF%T2M^<1XSRM+^TA9G!+SC4Y]):\LE8S?K(![)1^; M<[2;.^C$)6M,,N>PL?L2=^30;5K %*'RKQ^E'8Z:C?*1=,\R11TQ",_&7 VE M6\+/3<8GH1<_4405/2JL)!HB+S]I(_3\9N9KWPM#;TQ/^IX"+L1/#'_*2$S8 MCU7Z4[CXQX_&IU+=M]K]0#5K"6INB>2 M[COMS]TK0EFMFTO6^;/]:^OFEPYKWW[Z='5_?W5[\]5TFKN@\X_6_:]7-[_T M;F^*[++<+C.S>E0_74);IN--9'6U?#RA9%E1/7Z6J):K4"POK6=:=4WCW2(/ M-E3=W'#6S9RQ+Q'[>-O]Q'+V"4U<*?"Y)< ,/BKN)_8N-7>KD->E9TW0+5 D MM"7"-@&J4B@V#[&036^R]+*RM!,S ,:JV[GIL6[G[K;;^S9,T]WG[OWG%A#5 MNV5@3GMH,XT:N^TRX^C /OPVB+S]R'J_=EC&W">FOM7N,7AMG-;JZVG=VRPC M_F+>@"GA>RID!_%WP0%_B2!DX@%*1J^%?=AD3YJ+.P)Q'8WM-K0;.O^#MB-L M(L8MC:'6"-LNV7Q6F@$Y)>%F[5$C8]9W(7[9 M_C%96)+3DH[ FW,IK46_M2I[5<3T57FEIWF586Z7T=M;0LD\ 3;>@4T"!K9Z M /K87:O;N^ET 0'>%=EU^:Z\@5IM9V.KNV#H06?*K9 AN]!:I0QD/&#WOK P MV+8AI&/M$3!'J&6^XK"/TA$,A YS(3M#M%K=L&G= M\M:HMH'9'0/A[='IQMCVC9.[-5JGA8M:K58R3DZ,QO%^(HP?SD/>!S9:PG%\ M;M-J> &76> [F6VK?7UZV[^TXS_K!^7N>%0&NX4:V^B^Q! MLQK1V:Q&*@QT*?S'SB>DCJKO:.DJ??Z 2_$6=R(QT>.,>Y@OK!_7&^\H;:U[ M4/%+GP]%J:\$_X)KXM(63?[@@5W::FR%=<3!G"RQ:87%V^5:G@)0 M2ZN.M*S0UFO=;<]^!FI%\(*YSU#XRGO SG)PM58%1\O5S.&NO5QB@<_VTS.6 M2N7ZTCMBX6ZM18]/KZ)$N$5L?YX1KAF%"[-:JAJGQDG=7,7-A*=O OPBYG@+ MV3 MOR9*!K:TD.<0*ISW5>5"9E6'BJHA=^5_Z/OAMRN3!U?E;OF^S#ICW_%F0M%@ M\F+%;KSRX?PTPC^(7M[@T'<)AR+BGA*?5XC"-]NS$?UW#3)L[-/>U5^,P&PO M1X4+$,DJ^ZSZW&5MX@R[5/)AB:_+?R^N3J6N(L_<)_^.G\&_S0C,]G)2N+B? M@'ME1U7C*8YMFWHR7D_HV_#Q5O6\1W>?4]9X(?*R?4#T_4&J,= YXN,-9'S3 M#._Q>@RVMFYCL2YN[\I"FMW[] WM\E<#_6C*[CR V,[_2G\_^#Z9\'KUY2C, M=@-17>W(7!;0K0P9OEN,&C$,4]>^ C0J?>XP,176) 3' 8\!SHG@6T:B,,L, MIWDCK/D:"=!T2> ?/S9,X^0L8*%PA#_R7,%<"KZ*#%CO3!"],HA-<:^'NTL;7WL@B7I*=;WM@OH7UJ,)%>R2L+RP<"<9]/*RF)"8.^MZ4]87C M/3(YH)6@%HZQ--\T Z:%]D ,8F%*XM;!9Z+)#CB1-R5WB3P)FQ $0[ M&,RHOZB"UP<&1@D*34AFD7,"[2C&W5G\;N Y0#+6PQ2Y[3YS!K M(4A3F7Z6GW'VU9YXKKO"1<0BX$F61\R?J&"" MD@NRWYV $-7-HTB*47SO ?DH,MJL987LP#AA[8]=9M:J92B8K-UOF-!Z$^WM M1?O>HX,!,-!/8 7!%#J[ENN3[UJN4_Y TYI!BT*]K9WA3R5=2R:L@F CU@HIY^J:8 M+Z"8-5&J'U@OJ9A1#]LHYLX#T@P*5A3K"0718I9[4 )9JE7<0$L2!X# @/7Q MWG>PRMOXJD7>6GVC1=ZE:[LU2D-TC&K"!_41N^;E5Y;H%M)V?8 M>GAWASZ"8HV8Y? @V$D>_-E<^P99I#@J(VW_N)^-H=@;A_(&ZMI-S RS3[JR;:[ZJ*JWAP,G[D//^E)D/E?L@3L3 MP7ZJPJP;S,=;#D9Z55D5ZZU<$!D3\M5J[@3Z896 MBZU98^!YF#^^L2'%$QZCG8T/"2WB5E2%A0V:1R:8%, 0*+__XZDO6BP2<+64 M&_M#15%A*?&::W&#G!:3\XH&1D7AFZ .3X=+/+4 M,U&MV2_%R9]%"G+05I-2W[J+F'1$N/.]9890?N:AE=PBCE%[]^SH@UHH7'16 M3-L3VP_B:K]0K;:NM/\=T*MBPJ/:DQLHGC^"+NB!3>\8D[26IJ^80:91GTY,^S\ M44+7*&@NT =OE'B0 =0#2\%="U.]W**;$+$P7NMHJG-7ANBU0YX$J)E M-;K,HJEXR67@_ZKK9%;\RU[LYI^LQ(OQ@L#CHPPX[ L0*0"'SB.?T252FL91 M B1UQS^>TI^SF%/^-)LEJ^SWZB&V.4;_ZBTZH/"A&.-6G*IQ!L)HE%D'#ZO@ MJKC'.(M7G=@E^F=)VZ!:0R4HK13[IU4$'Z\@F-@"E@2:P$SB=@;JUF5TP4"< M;-&W#!2?0,-%&HL^Z,6RIPP.T 3@^,WJ663@Z9MQ=@AUH#"=PXY]$TF2V=)6=IKQ%Q: XS13]X"@RU4"GI M))F$IV >#^2A9E=R*22>1X@XF&4&-V[8%S2>2GR,A](_P#6_ROB2LT2>8I32I, M+7@9K,LA*!IFN5BD+_&HB^Q?=Y_HK @>*P> 9H%V>BB!'%O-D[QX',B8M[0I10[ 9:5P[-KRM)S 8]X*\Y-A,_I+ M4+Q0;RU2>%L+1#4#9,'GD(_8R M\&7(G8&1B =PX,X*+,*=_>5"'X=TN$XSR M@6.Q#9!CO, ;H9?%@Q&"'$L(FT2 ]DE-)2Z 0TL_&65#4]>7CD,V+H!91#O/ M3+#P>AL5\/"#L'B,R6+2$;8%DSZ"J1#-OB/_GD@;Q0_G#<>$_A3:HPPTM^!M MA. XX*L''2.A*0S Z='I)S<$FAP4..@(-!18H00Z3H:WQP0 *4, B% "()@" M9N"8. ZBD1^$2HR*I?71XICK#F=E &Y@T3&[X$0BOM**)=*W3AE!<41LM.<: M6EV]" 0&/H+,!T%D9*PN-#*Q1'8$> M B'T!/Y4W7C)Y7- DP4P/^.> "]A9B"4(:>E7KU'1)@'KV+ M/<=#U.(C1]N +1I0!N0:K0QX0]>B3:]DZG'Z="Z0AZ&2_8E> T)V"(B&0E+; MOT#^M%'I@TU6$S^T9M%-46C$(1[RO4#03-@B1*K=2!Q]F%,7F$- M)4(>( =Z1^3 FRBP;@&"K[\G=*M+',YISJ:.O5;5YI+&OXXBD&<=0&]/6RR+ MJ<0O%_@G?4AC#W#;)%@$X6R\H?0[0-R-K,N+E9ELA*3TW6#B0& .?U?9@52Y M%\T)&'.L.5@*F6,7A X*G!)7X&RBEQMW !X.&-H7 HPF$DQ ";K,FN2T2!C- MCK#+K)=QD\LH8;;4J0XP:Q.]"QAO:YLEC>@\APO0"4M+-#"NJ],26K;)SI(' MBAB ,]:'SETZE**R+;V^^!*60(8X(I;>5@8/ +F7$,A[\5=XBQKYI-[M-6CD M ]S6#?,;S,E>SZNIVK_Q%$/P7)O3E@!PB;4Y(=7%\&,Z)+RD%5;#"B),[! M 7@'&S3$TAR-D4W.*#5;\PC4G ,N,3N10+3Z%L9I"X2\=]CL-T7X2,I_7S$M"+\ MSXW)R^[[![%()>MU@I7[S$F&U'-:#N@CFN-HI8'<8\8K%G,L]QUN8?H66MUV MA9AF:W\R3JNYR27!LFVR'S"G%/9$\"^6 MZCY)$10E8XPKH_&LQHCX=;C?\X:T#*;Y&3YZ>:QM"P<,!0&[)T(W&$T^W,LS MX)4"8I#\G$=Y 6T[@#H@R,)@Y0O6,]P*'HY>U[7RJ ]+]B$F%T"-3- M=""I1)08H$E5 L]>4D8)("^84+#? (%0$PGY@)8(M1X;'K 0>EP+2+%R9%Z M9@W,@F72O9$<82_ZH _F<,C;NF3[7)PK"C(BV<)?_(&^<)="5#^[V2YO=X>X M&B+2$"E.$>H\I)M(MY_^!$4\.K(KB8234'M!(!'VBZE0E@P2:=<,3X!2;&"9 MYW\;6.$$L4)7#"?:++./EP@.T!J!2?BF$,$CH"[$,,QS0C*T2$?8N/;II_D"H$O=,?ISU([F!T#]#J8*%<&(PHJ=;7.="3[H)"GI['UB9)QA'*3.WF@!CZ'\?11 MZ2-I?27[2N X^76JF,GLY&7X6XS&F"8LPCD",-:$;V O@)0L0S%& >+J$BLT71JO6F:0K-HC MT\ILL\KLNPE2+=HJ;Z*7+"^%1=NXHJ2P0=BK5DRRPE@?%X>B_/'*XDJDWI4' M6;=KL@R$P7*K/8G&-,^&,5OQ^\ ^W%*:$@.ER7O"3!&5WX.=VN X"5DM;1TJ M:XU$_@P(N;8EMJQQDIP"V<0>;GD,9!/Z-CODL;UQV^!X ,O+5:GO>-:7G6_N MCT152Y>^KV5#.Y_?J)W9KLWV>;YF"XSR$F M R]B+0 P""-WWQ?,PM)2+Z 2^FS%4XY]PUG!(&I' K1(!'AWSO1/@]J-:KUQ M4K/%]/34*(_",1VCS,3.V@9ODQ5/EKGOR3+U9*W?_T= X#Z[6K?! MWK[%2E\+EMXD)984HUI_04%I>_ 4)A3"^2OLD#8G"7;)0ZY_=^, $:6-Z!+S M =%2TQ5Y1X8_?\[LZ%>S#C/3]11&7PJWV )8R,&O%XR+E_@8\RT3L<],Q-*? M&[WZY:;5^]Q-?O[T94..N\P9"'U$@U9:V&L">XVPRW"]HZ M=1?],!VTVM>;_9)5"JG@T8@[ XRS]'8=W.BIBV"TI;=G4(LP)2-/P5#LW4,A^Y6/W5P< M^'J3@.=S]SD-BTQXU>'3H?1]CK^37)S\.Z[<8S0E[7@3=GLDQ2"3(KVENY75 M$K2U#R^)/XG:7+;+\$"T M!!O3HE+\2)^TLWL@Q_.*WW/GL&W43AV M+OX/4$L#!!0 ( ,*+DEB[JM2R+!( /$U 1 9#@P-#@W,V1E>#DY M,2YH=&WM6VMOVTBR_2Y _Z'AR2P20%+D1S*VXP@KVTJB'2!G0$2B6P6J^MQZE2UIY @)H56_R:"[\LEME<)]W"I(?]M'@CW/>I*0H3VTLSDQ3=7/^N M#K?K[S,9Z^CV<*)CE8M/:B4N32SQIN'9^/VGMUL9*;DU.#H>C&X6>JH+03L6 M1R^/!TWU?DOGM(G)VZVS\_?GUE@/*KSS@PH+ M"H'A\=E(G(S.SJXNAB?C3^_?;O6W^/O%\/34?_\Z/IU\>+NUW>__O"6.SR]/ M1Y=\W>E@KW01)6?#BZO1H?_P7>=L>K)R5L#18RW$*EX.W(=3K\@KZ '/34[K M.U_I.,R6ONSK)=:@.Y=+H4/S8E@8; MRL$M6^+R_"MLC6^OX(R?]K92,B9BU.=J:# %3,3)R9+328+ MA4]Q7"8ZD(4V2;Z1,G^V2A]5B#=%[=9%9E*5%1JW)UF9%QTQ3H+>$[_]^>N] MUR_$T;OS3Y,*;!>Z4-T\E8$Z3,PJD^G68']_KWNPWS\X>DDK!S_FINT?UNKH M\R"<4F3\-;;622O;%&2:7F#BHY>?68\Z#Y\D!_\G^8YDJO&,_ \$YL[>GUA\ M/9ZC^GX/)-C#]-1I%$1\O)E!^//C/;> X V#F3K\S M_8]2A[JX!53)) >>$U(^CB./+OBF9(:==$]AG0IL^"^R HSUNMURUNH(X/9^ M_V>R&LSSEY^V]UZ_R0&:NM!0\=TWL=/?V1,3&$,5:\:[/VS_%-N1L8YU%L-6 M"QEW8$H!Q5[UW\#MF8Y8@^.!^\L6Y.V=CM74+J1[PA4%4=>$=JM1%,3S8J%H M_=XO;U"L4IG]E99/_-"_'\TS?0*MCHZPL8,92W0B:)*9- A:)8 MR$* T2YD+G(3A?B<"TU^!]32)S'32R4^%W(A%B9/-;S/ 2E%HE:(WQFX.^3\ M9O"06")BRDPUU?MB+WE=5KI8X/40O,0+8MP4LS()FT^\PW>WO-V2LYF.-((A M=(^*2,F02G=<1H7NHA[@YORVX[Y/72:%)HIDAM?DA2Y*BDY84^8Y(B&FXJ\R M+P_)"+4%Y 37 FS 9"%M&U 9":A(?*!6-N]Q)I*U,E5(]# A[4;6*2UV7OU< M&9 $T<:<$; TY.^T19&660!!=R7\\NKG=JL2 0.+9_O[KVVPQ#[V9V4$ZR_1 M#(6@*;!'(P4@766K3!<%-@9[Y4I,Z0\DBMP$GQTKU]FM)ZXT&5(FRI2Y-1$I M'$0FIY= 0K'0"!49*3*93_W.VC;32%)L(4 4X]E?&*2+IF]S'*?\2)7 >2$ MB+U$)@%>W&$W:7;\,[0X:\;@?85 (^OE@+#30>:4[8LE%-;Y0F;*;D&1/ NN MY)-9F>%:)@*3S&SRKMO0!@Z,72I$P%/C[V!B@%C0QUJU6)FFJ7,1J@@Y2?:Y MX\WM-6_27G5,%(K"BNV2KM>4CI@J!!AN&DIWL@6"3F5+VN=DS4R9:K?430JZ M3+!A\* H<_L1JI0!+%L6R)>$G12J:>&13R=!5/+55-YRRA.L('Z]+YK!_VRW MO^'=84E)#A! +JDL%I'!I[!4%C2MREXP!$Y-EID5URKV(;L^4TL3+4F% ,H" M[V8R *Z@?CD=.0J0:7,NTP@BWPRT6\C3U.3>\4]9.T;A2@)]?NV)811*!/W? MLA[:HH5$3$KDV 5\ ^J&?9*Z)PNM9F)T@UPI"*// 94!]IM+'7;6JP"! AM9 M!IP:57"313RLKT$>@*G=,B@10LX!<_ VTL"A#9P^O14+/5\@Z'*3 A *:I:X MG.@L[*8R@V7I3QUH%"=;2*280@&HSY&0Z26]!R:[5A;D^/65,IQRL/EYF=%B MK*-:$Y3DRQ@:Y935,@A41+2*L0DK ^F>CB)CVS=15P@RVDI1) N CTUVMB87 M0=Q9(>(HR"GB69QV7**P' +1]6RGUU_/,>PLJMC06I[B#H=H!4(4ZP0BMJ^$ M]O#@TMX" K(FS>=]M:"HS[WF='-)V9ZHN8%RO'4R7P,!FU)ZCA@\.6@-<_A) M+37J!K1#2IH,$6$AC.E#I.!2< .J=KZJV[X[CDURE6K$H_B ("@6+Z -6$H MLV++)(&K6+@6HO 956_$O%#_*&G;AI?.L0@F(]$S9$Z[Y6*,X;LRZAKF;);! M9M&4!:^?Z1EJ(>R,>L 4)B$,SBDL'8K!U[O0.Z=WV^?1I0*5 D709(G#')ZA M/$&>$GM Y,2Z8 804CQ6'H0E9T!X/)O[;3%G6 LEH%*NIRC$ZD9E@H\ M)6ZXQ$8RFZSOC0F!Y-P(D57/SB[X^K&\QK=3DZ@HARTN3FJ9D9K3+,6)R3DS M8'BW6QJ IG]TRBJ:^]W?&'X^^=#9-U_;7G/JND_'7] [N $Y#QVIRT^!<;>1 M6G>ABN^H0I<::Y3]V1$3??_NQ$^=5G#*8C)/1U5<\KVV&#@]9\XZ7M !1M:=6T( MAP\T(H+G8+[[XDK3W^6^S($FY4F(ZA*9](^0<%5T+<1Z"EX58L>4-!&@=YF) M78<8*(81?+**KS6]D9S*6%KL=_TI]TQS,+/$DD=@(Z HJ?CXRF11Z+$JHGJ+ M[6$U)3&6W$M2N#W9VSUHZ$C[1OJO\>*]W4Z_WP?6(J?(HE/BLS 9B AA=)D4 MF7L2ULL JE H4W0K076EKH^0Q.IRNRWW6UNWG=[S?ZK:EM$;$#6 MO7H\_6'_Y+JN\*C\EK3HWV5]E0C,"B]-B=V8=1ODEL*!X5Q7E(+LV&[AF\[6 MBR33*'J V^R*]NJ8^U[N:>$G%2P2$YGYK2A3U*C0F<-P5]1H?\EL5B?F%N(= MX#6F_D$G%(K2]H*I+7]+VFW#W9W.Q1=$O)"*I)D]O7GMT=@XG<$C&Y0S9.Y:DC::TIBWSRD=@ . MYCH=Y ;!>J8MM:=7E79>L+EWI"F2)R_11^!=MLD 5[,DTW<=Q*,WKI@R M"MQ=G\R4'R:!C%MK,>=K'5]$D&YI)1 MEPQOH_5P;0MF( MJKO/%-YA.ZQF[I.$:DU-V9"QG/O8^7>##J+0@RMQG5 1(&%E8C]G.K]VR$U3 M2:;&'.3^?!R.5KVDTI*DI MT4E(8QF.,KB/5J($1+;EIF=B7UU((%"+FIE;HOR,6NT6GX6\@BE% C6 MZ=0L 9')Q)):')XR!9"9(=CAW8S#E"8^=L!S;Z6Z*A0/5&1AQTU<*#L>M"45 M2O0/5CX* D6R-B&)I-XRBEB]^_5KM+KU,-WP!!'A GRBH'#E[-9F8(Q]AE[=!1/99YMV1%( M)=06.@<"K"%'%3N]&IS;T[;:PN ^Q*2:F02.#7Y)'!%\"+?9&@W5X"A8?@5* M@WZ<55/TD=A)P* #C=0-U2?'BFD3*DPH]VB !OICF6Y.^M:8I]:[',29 UJ9963:FNZ &;!.3:4\UJ%HUV!&>N2&8<-9U\PZ M#O<]R-.@*+(SK,)TW%2#)BR-IQB\%SP7$@%"&L9\'NEK]?AIX\GYE_%I=_O@ M1<=W-?>Y7J):!$63OTOG3V=<>QF0#YB#9SL-/*P NT-Y[4K2K$&165:55=9P MWG)L717KCH:[$_6?,8"I=]P@ M[X[S[B131!0ZJVNC.T)TA&1AHM"2-#Y2F1G;GC) M- ?O0@63!%R6:M/<3F8NUV]\<#BT%\"5K*+VV&9".X:-#.X&P9*<( H,;0>SD:3WBXANU1)U_(&^$/2AR% ML!(_]Z[<: /6\9=^[=FWZA=BID(^<&&TL$-M+7+:P&;E==SC0A1(2Z)LV#56@U!I M1D"PEINJ[M8E225+G9F$8L\""&4FF*W>:+"LF5UD+1_@D%PY?3_%)^KSA(C- ^IZW=A&Q7-O.(W&Z;--T@.Y^=,4$#, MW8ZRN[#F3MK)GO^]IQ4[_SNM^->FD#Z"0I6#ZT[I4&N*KM<=6A? BX5$$2?@ MY3%Q?>CK"0//U>[2VS5"R:.6>R08_'B?UVO_MKQ>E1^:D, MT^]14OOK!/CD^].JR0/M8DN,,Q6V>R.";@W:MB- M4[HL;*]'ZBSI9'AS!$7G(-^9)E=GTSDXNQO/P":6:EAVLZ$AGP?W8#]I^2KQ M;UDZ1Q1V9L"_QJ+)&HV( ME;IF0-89CP_5[.Y06.0UE** S?V\G 4T#*# )8B_Q=CMTY\)W/D9['CPDZ#_ M[4])_SL!>O?[ 'WTDO[-%B[R/_7Z)U!+ P04 " #"BY)8$OU/? M?KFZ9Z;[_*K__?KB_*I5;UX<'YWWV_WKUD7K_TYJM=/2^:?@*US_%#Y SB]O MF_\BE]\:M]>WW2^%GU?M?JM >OU_7;>^%$S#XB=RY.&^V_XH>?C2&WNA,.ZT85H$PT[BWH %^YQ7$:SK18V/FW!O6B6=/ MSJ2)]YF$WP>VY]GCX-*=;7DGKO$_?B;/OM^QL6$^G?6-,7?)#7\D77O,X$WU MZ_:WFR\%!SM9N#B_O#C_='G1^C4R!H9'Q*@O+PA>.__4P9$OZXA<2K GNB"- MZ,KW5K/=J%^33O>VT^KVVZT>Z7=_]/J4M&\:IZ1^TR2]'Y>]=K-=[^+-WW0S M27K%>]GI$^Q?O=^^^48Z]6[_IM7M7;4[E%R?=E+3S1\W]1]-X,XFDI-\O>U^ MKY/&[4VS==.#:_"I=WO=;M;Q@:_MF_I-HPV4;]^(!_OMVYN-F<#CO[P3PQI" M5\[*']8;AV#('Q?_M W+(W]!"[[#2=]AELMTS["M\T\_-N?.-W6L/^(N)[[% M_*'A\2&9.#;\ &23>P.NSGK/[^ZX[N$-;\3) MWX+P#R'AO1GAR9"[NF,,H(T!-^W',X(SL%Q/;6<";JWCH_K$,PXC=2_.,/N5S]W+#' M$V8]X1?M\T=!Z[D)(<_G8]-7+9_DZ,WP^R$^;#C$0%GG+K1K6,!N,*T_/#8B M(]N=&!XS79Q41BS^:#Z)R89WSL]O7YH^)[>/)NFVR(VOF]QW MR16\7K?)]74C_NNOOC4,?WI*0%)(2"Y@099@C'_*IZ6 .0:& M:<(C@>Q@N]A!,O$='3KTO"?5EWN"A"-_:IH:-#P.&A:#A)L@4\2R"3;BH*0[ MW!1]PPF#.;7%['LC>!VT"JU/4-2@W[$74) G[Q&%%"X>'X6$"_CA!>Z:&Q1T M#PD=- I,,9.&TYV+:,\8^Z;'+&X#IX@9Q&[JINWB&$07#9>XS)Q3+308>43P MBX[,_T++X8)\%#C/1A#N/ZG7)/F)E,PTA"T.GR&.=29.XK48<3& \$U\"@* ML3O":0]G$9K5@2U#8N_6(H7J)> 5[]&.$]4%A6V"2D!*/),2>4Y*<"ABT-%8 M%D:_AZ'57319#P;P$?08C)?M@,8,!BITG,E=EX,"0T&.&![' 5T>VU9O8CB M9J\X,[W11^C=$V'Z?WT#31JT8'(QG0[<)EP89P(,PN"5ALX)_Z\/UP,2'!^! MTD'AQK;O&(@7C/0_W!-:B$\%,:Y+GBFAX'6"A? U^/R=<0>R 9+K 750S5DX M4RYS(CE&RZ; NUQ\=?!['4;&+5W@B'D=>P^SCO9$!W,'BI:8QE@@%.P=8I.( ML8&B=\ /T,9TAH4&F3*WX&?;=8V!"2/GO[BC&RX/R1)V+" \ZGKULSO5J,2> M>$(M[EKC_$3"F":H5:"@8)4[U+AB="Z?%P@P13.+-8P'M3&V=X/TI_ 1X0[X* =L,!#F]>L4<+8M@>U6!10J!/?1L1P#6=J)8773C 1<52V,(=7 )M"TVX_@25O&@! M%5=1"1\14QQ!I[#M5_E*##R&LJ-!(G,8%JA1& &P@CXBCWRF+T+E,&MOR>\^ M4L)_83\"1TI,AW@Q0#0?@88!"AD!'LBK[V"G 0VY@;)^M6$!,O'U3YPYA%L( M4YH<=/V .P$5%%EX.PH5T^0N>&V"UC,$U5_0>H90'F!;=$!&3J#K_\DL'^Q- MZ$L%C0<]74-H!\P48NB..-A$)M36VOU>RB/Q;G,&)46BX0KD*"9+P6I0!JMZ^M. MO=ELWWR;?N]UZHWH^\]VLW_UI2!+TH="T)\N4.@)-,$74IBP>WXR $K\!Z8) M_&5^QAYL8Q@^V(Q^7/LP&U2_N7!3_E @?X41,B#*-%H6A%O1WM=6^=F2%\0; MFG\6^7#N;DA>,C\YY.70WXJ4OA (%&RB0(.HABS;FT&\-_+G9V1)#(!W+L2X MX9\N_H,<$Y>UG $/FP%C\3%T#%"/+8U>1 _\7C$^MXG'1\N-R]0/"Q@_",(( MOQ]TJV=3$IE[C"Z\ B1_G/9.R3<./160I*[K?(+=@P^V;P4C<XT M1-/#F(DA@J78W=8O\.JL>S&4L0$.(2(:Z!,?.#/04*H% =C [#Y7#J@TFNV_ MX'NX^'5\1,3?\TD@7/,&FH^?,2)>BDG?@,, 0?K,1_;D(G]_FN!+KKJDU_XW MD$T2G( 9V\9H=,+I <5:\ M2]"Z$6 8 7!FW1JQX>_PH'@.;9S)O5FT8BBB_F&7^/ 4/-]I*(\N /II/XZ/ M8K09VF*$8NQ.Y/C\+<*T,*H[7_1D^>! VIZ/+3T@=!DK"-](!(FXZXEXU3#T M)<5M&@.B#\PPA3<68Y(@I!2&F9CK^N-)0 KA&T)O0%B%9S/@IL$1[S-!/>8" M@V%;/HPQT%&ZX>C^&'J&X:C \8@W*!XTGT(M'AM5K+>B\3O?$4'VV?)4J(7C MB.CX*$E()'KKSO=W'L6#F&$0SL* WB+Y(L*[4PES_<'?H5,4J%WA_<0BTO$F M!AP=1G6T"G)M?[!;(58'H^,6*819YG+,%;0$[&"J+M+/0BA)S=S(1:1_2+RGV.* MF(>0K.NQ0"ADML"KN @_3!&^6@:W06"GZ9T(Q =#G7:Y%#T8//;ZYWTV%EU6 MMC(R 3%#%RV2&[H B#B@$*,B!_C,#&D2:")\$M]!A=V,-"LW/;KVSQ/I%/WV5(+.9E.57VBK60U@FP)CM MNX .W8^_:SMH;DE?MJ$F@V#/,BK'K/A*T:7P$@(KP;@(^>(^T$ET<=WUT[KK M\DC2.TE,_JMM;'HOBV_=";WB7+L]9;$=/E82X^-N?%]*R- Y,V>:F=/-NI7$ M6/<:K!8E ]\PAX9U'X0XC#%NO>-A@ GP&[/N<8=1N*\IX/!PES.&*;),3O+JN^V,\?L.'9,@G#M>-V#A-:"^G4(Z' MY')AI6>PL5X#7UXPUY LQ*9^@ M0S1_/<]A2+$33(N:4F%3E0JM[7JCS\9!CPJM5E=97\_,9I]-9ZTDT9*\YJSE M!G!^NX_8:NY;<^?ZXF[A7*K(E(BK3,O5,BU7LK%/09:JM%+;5E]7E-=&"N15 M!I^Q!$;SW>X-VI5\VM,<$O" R->0%KG$-4RUG&_02R]LW7".?NA^!=4++SAS\4,!2MI4YZI M9G\R]Z9[68:8R45N8DR=VDS13L)VDK&XP9X=IZ^ZX*)KE8 TWGZ=#Y)0JK:E9 M.>U.I?(J^PRWN>.RE0*1*]5H[2UKV8=K"V\'IG$?5@S!^A/<8J)V193N,$R# M:+[=E4IXNU!%I:JT2IZ'_8MIQN'I+FTY13* M8>U!PMHM;.A,?B])OL%SL?OY!L]\@V=V-M7MPRP?#(UR7EQ_@R=<_20J\JY; M"OTM!8G["V6_25#U&VML,PLK3_%[!TNU,\?#4NZ>J.*]2=7K> 7YO.QU7O;Z ME;+7O8A1D./:%A9O3[CXM9C3C%:_KJQ:(UI)LF#U]AM+M ?;\'7>=\EK%$F\ M#!J>_(LSA[1 -H=Y(>ST%<).#_?,40L^D(AY\'O"_/,.)%I^-BDO5K$6-.:_ M= Z3 Z"&P 00=X2H#$PD^UV-ZR70<@<%Q3,0"^H&>_KR:M=;<^NVUN?L1"^3 MK&H-&'A@F"8HTGV?O"":A'GF=[PTN$%]WYI&*RMME=WF_M-O*RP+;F>:JAA MEM^P%)@U ['-Y+OI6)8ORJ4JU6KKUNUY*_-MNAJ-F2NWE0=JM^*WZ7Q55*JL M)(*_*;/T[B4N#.[<.?8XK66T0?3DDZA[49"#H:^V0&UR9U> M##:<.=-08QH,J@9>6;66C4,4Q9)*:[6ME1=.$X+5RF6JK;N%/"5:4F2J:KM. _VYJYCBFK]5HI7Q N#71F'Y0V#*4M3RPGP?V M,^!N7=NN2VR+N,SD>&35F<4@TV$LBC+55LI$G(+MPX?F;VTT-UDV%]N)]!C.3K[ZE?&TIIU"^^I;X MZEO6P&[2ZW'V_$I!&JQJ4:FH5-,RDJAAMS[G?@,[Y;)"577=BV+:61%?;B[AT^3%,_4""_,G1-X_]VD)YA$T5N(K&:J4C,2FPK')-HXJZ M+?\Z7895TVA9RM]DX+'YHX:&-YB;'L2E':3F%Z1HQK!LBI!KI:)2J;:UA+0YEU=(J0\V1ZZ+(H;R% M;B+S/,<8^![#BD>>3+E<55>OH#HU MP6^N(KM)?XE=G.P:WZS5%-V'>3@8&N44/H = M2\DF*XT.S& IM\CPBHINP1(&&3#7T,6^_:%A^B)C5G[Z>0]V\2WW,@4X$X_ M(M[,#LZ43FO/ZD_N F1F428V)# FMLR!8MI-]$&Q\@'-ZQZA5^K,TT^.>HD/ M"7O@#@PY@%XNL7W/]0!SX?&M. Y+V#RM9#R>J] *UK*4M72%%M(JV?LC=V*]R#6 ;D4 M,Q+Q#JQC#A;WU?1'G#!=M\<39CVA';!L#WZ (6-FB5Q+]YCD?<(<#[,.>B/N MNP2>QAHX%&:*<,,P\/A(YU$2VBE."M,#Q M-MM_P> ;HC-P@8B_YQ/B>D\FGQ\]&KZ%P>.EF D/CA:=,?.1/;DXCY\F^)(K MT$KM?P,ME4+4KO!3S_ZHB3\%\K/=[%]]*=&4-O=*:=5@R@*C.->^M+ 4UW <>Q= *E+Q#<.4$6.FZWNFUSJ(/ZV''14(AMP6F M]"+\T(PZHE8^A"IU>F?1M(=/EC[,Z=[7/Q](8]M _]HKX']5J_W[#9' 6,"F M<*&TR"W10$(+%#*\V,?D+>YC"A1%\+;;"<=*'=;]^67WH@.JW>*..S(FP5U4 M&GCCRG ]VS%T9N*W)M?Y>,"=X!E%IGBQ))6>+6]L2HB=D."?-IBTX'U_00.^ MPW$8?8=9+M.Q8I27 )]86?VRG[GE,]DY96VBO6Q[6-&,\,"M&G[ M+K.&F-#L];:#YE;S35.Z$61+*8M#+LAW>!S 6_>X&+?(_BOX$]O)VW0-^H*2 M@6^80[$3"OP,]=).S(*W3ZJZ0O+VN![)*9VG&$SZD M].?OGWF>W+BD5*FL[3C!\?H]+6I:E=:JZR;V?6M'5WUPL;?U'?=S@ZDO4:5< MHR5YE0-J^UAE25&NN+;UP ,7 5'++ VR4"\I.6HH@R3+5%6R408X;1DWDC/X MJ9C5% &%/8KM=]OQ[G$YU+3!_T^'F"I2C2HKE6K)A30K0KK1G&9W435;QS?W ML3QY(!3:CP=],/.2':1=3:[HN(/'/XPYO.TD%NY*&)N5:;6J45E9)2W/_JWY MMCWH]V#)985J-8G*;\D&DC6\G9SPUG7='_NF6.(?\HG#=8/AFIL(>+$QH''C M?^)".N2W*-.RA"*1E82PDDRKNX[4924 MCD/*))*Y;73-.7P/>7@-*=0.@ST MP<[+(<+W(*5?)L"[0I4J(#UU%>.? CM5U=!*K9MH,N6Z(>$I+=&*I@">>T,D M+FO@/;E-)0WFC@10U_$#UN)]8&:P*2X-\EJJ2%22LU%M4*921:-:-2-Q@!'IAI6:XN5T!(\NH0[\G^;C*E MN>U%>>UY#D,:GIB&Q5,JL*I2H;6L1)_D"JU6MU:4\#!#96I)HB5Y308X3.L; M.LUT)OQT=G"+P@.$9Z1%Z7,E6R_GFT?<$R#>B#GB* M]HF6:B6JYOM$WY4\;C2GN5F=R6>:%I#*E2JMR1E9/:JL!.8.=N4(YU)9=R5P MB9G,=X"D:7]#3J%TR.K!SLO.@/2F0]Q:;HJ^[3&3))ZA8K,<\K)&%:E,M7)Y M#XDF-ZH&I:@*K:$].I"\F!O.JJIJ5),J>5[+U.<_W(>M.!@:9 M)1;W]I^E2J*26J8E996-J2F0DV(K&_TLU6@M@916[UYX;P>F M<2^26KA8J-CC%D-[/4WQ&N2().;;G7)):()-B EL'23]'$UJE8E6M&R MN%(JER MZ84JJ>L8T\5RROT1Q]U@]GC"K"?,*F/9'EI7!S>*81U4?N^ Y9TPQR/V'?%& MW.7$MY@_-# ;S<2QX77.F!'=1A/OPK6Y=#5AI4-F'A^)A%4BKD\GG1X^P86'P>"D&@ 8GD-_ MHYEY-(;>Z$P[K1A 568:]]:7 @*? HYCK2JW;YF_H*8ZN>VTNO5^^^8;Z=2[ M_9M6MW?5[E""==1)_:9)>C\N>^UFN]YMMWHDPDO'*U>T3:*;/Z9,,ZWJ3AI3 MIFG$F:87<0JR7-L"[N333L=(&^L0BL;"$)Z-("Z'8E*%L)%&ZQJ+CC> >%\* M4D%\[]2;S>C[''-HOP@_- MJ"-JZ4.H6:=W%J%,^&3YPYP*?OWS@32V#1=*>\6#6M7\_O8Y HP%; H72HO< M$@TD-$0AQPL?TUOT,0-]$;SM-DHE=G[9O>B AK>XXXZ,"0UNH_+ .U>&Z]D. M;F8(KH/H!A_ &.#]?W'FD!8(\A"_-;G.QP,>/J+(%"^6I)+R=M]AAS3ZITBK M^%>05A%'T'>8Y3)=[-(*^@%:#&\(188?ZL.__3!MVS:&&A_:-M9.=LN 9$7> MFYD*^!L^.".4EBV*(,MR.1ORD9\KV.*CRQJRM=EK8_.24R@=!OA@YR4[J#RYT[_!!D5G M&@-.@V77P$^MUK)Q3JA84FFMM@J^/-@2 UJY_+:SO5F#X(DNS[2FJ:[RY9D# M>6MV[%#RSF8Z+%!9EL&YS"-![\D,;32G639#2:Z=S@JW#OG$X;HA\CX%.1G' MMN,9_Q,7TB&]*BZOJAE)&]OH5UU%<\F!3*1%=DMH^BNZ?SG9AJ%^1NW.!YZ M$59Y.#8LP_5PL^I#2E9LY'*%5K1LY&S(4?46YS1?BDGY0D-.H73(ZL'.2W:P M>-)+,>DJ;2#3DB135=MQ^9'-G>D2E96MY4-_#P9;TVJT4CX@?)WH:DQ0C#V4 MT7Q)YF#>FAU[E&#U-]MUB6T1EYD<#[0[LRAP.HQ34:;:2H4:4A#5R/W)+*NS>H@VML4< MR[#NW>!8#!=%A47V(MP+D18?$%/N960U1E-I=:52;"E0)\6KC/2S6EKQV&IN MDY=5D@7@/#OOAH;9MWS/,*&%8>P@W(!;\%A*['))RT86\-PB;VD^#]$6![&= MHF'IIC]$D;P#X$P>F.D#GIXE21(N,==]1^3S_9@.@:W22D9BM+G(;FU&EPAM MOJR:ID7#G$+ID-2#G9^_66#1D) M*WX5C>-*I\U28,GEFD85=5OQ@_=AR#6-EJ5\8?H-F=] 0-,5Y985K$F;C3P3 M>=ALBW.:X^V4H\F<0NF0U8.=E^S@[>3,-N#M&^Z1HAG#W"E"V)6*2J5:1K*3 MYPA[A=AGE59+JY H1]B+HHIR&KK!S/,<8^![#"OY>38Y_WI[TY_6?AL9'C]Q M)TSG9Y;]Z# 8@65;)SHT[MBFB75M/N$/+HZ/4K8+K:AD)2ZNEM=,\;\OB/P7<,:Z53S$2<8]JTHX*L,6..$M\M2DR= M9?S)49_Q(6$/8 7ON0"++K%]S_4 ):)5C"/'A*WA2K;JN>:M8/5J63N8H,N^ M;.*>IB>WC+EE3-%;#X@?#M=#7-T.;B-NDEO"5+\UMX3O7O-EC25S2[@#2PA7 M/_7KE]>M> ]B'9!+,9L4[\ ZUB?2&CK'77F%B_Z($Z;K]GC"K">T.Y;MP0^8 M@ZD?10*Y>ZP$@O%)3-WJC;B+UHKY0P/MU\2QX77.F!'=1IOHPC7X)+918!F@ M*"\5,X^/1$))D?GFE" M<+S-]E\P^(;H#%P@XN_YA+C>D\GG1X]V=F'P>"F& M&()C?&?,?&1/+L[CIPF^Y JT6?O?0$NE$+4KO/"S/VKB3X'\;#?[5U\*LB1] MF!*HT;KIM[I"X4$;80_/H;_3+9#&T!N=::<5 ZC*3./>^E) I%# <2R=0&D+ M\P=:_'NKV6[4KTFG>]MI=?OM5H_TNS]Z?4K:-XU34K]IDMZ/RUZ[V:YW\6:$ M)6!8N^PEQKZA?_5^^^8;Z=2[_9M6MW?5[E!R?=I)33=O!/M[-ODQY?$.\/A7 MP>.-*8\WXCS^->)QTINR^-+NQ_J&LKPPFF>#B2L.H3-0.41M7=YVFZWN"7#R M=;W3:YU%']9#RB1HYDM!*I!&Z_JZ4V\V87ZFWWN=>B/Z'I>2""8(>2)?R$O M?0H8PA^70<#B:YC1# 2"4ZQ_C"OF^+VWK7RNP10 MR M^"@V.N/:#LP_< O>^0N>\1T>*+>96H^4^G)&4',^6,('E^GF XM[1&?N",V? MSODPS+J*3/!/&VQFQ JD[S#+93I6M'0Q(1R!-YGXY>/96ESR!G6Q.'N+LQM. M2*WT88X)DN6N!3V+)C5@G(OP0S/>CX LTSN+?D_XI/)A#F"^_CD$6-%K#WB[ M1F>.9;_ZUG"6+?B!!ZD)$SZH\>?OGWE66^3M&>L.;"9#E?.//^2R^MD-$DO. MY85E#BBC>[Z%^=WX*-LJ9^[2L9*6HFF/V11 (>DY5B6O6WHXN^&F_(Q"ZH5$ M9.9[AM/V;MAD*AW.(;1W&8537X@[Q/FX_&%-=OUJ.[%0VL1W)K:+]568::[G M8V#@N-3][$0L&DP"V34&1/3AD]#GY.25"J+?;Z8!E/WQ*^A M:=&BP\?,P/W!F-_H( MG0#=H0/+.(%",CE#K>?$RUQY!/2N8^@<>0NN>_;Q$3Y[#T^!JL.V119_&-!_ M@ '#9/Z@D$1,< *:[9@\_?&7?>B( F\X!= M1]",98!V=IGS%&EAT*<*O,O%5P>_UV%D'%0E .%^HV#%D*]W\@J&%;@7$ />H::#?Y+^[HACLU M# ')(RD$C:N/L%_V!)L_)3\YV),'$1_UQWP8KA3%W_D(]""#8+G)%SU&90XV MB!'0_<:#*#"/)(J52X#7N#X,#SM<[S6()E=P9T2Y^KDY_8DK1GK%A\!I]WA3 M^XP$,MS(NJ"MB12*[3O0!]?#B0\F+!C>\=&L#]$8XV4;<.*@1?@-IV3@>\3U M]5%X$ZZ[_N!OL'O832 +N-DXKDJS-3]TTF+/5+&HKD"FI5!=5* MH8**F2X'S1)(U6\7#. SL-U7N@J*?%5%='PT57I+55;<$$2:2VBKZ#V! MN@N_Q'0VF-]!"-%=N.[JT(O _;BS;0]W%!" $[G*>S,+?TLE"X]M-,(X[H@W MPHP0TQT?HG@H\-K4A?V]4D3[:0 X$F97>+S'1TM<7C2R E@,>6S?28@^PK<@ M/'"XR0*76/1,= 1M\G1_RJRST0_ MT0%#AXP/EBJ?"#NB 4]&QJN[KON(H]? MOC,S%<-2F'8X: M:0+VZL&P?4!*!F;\M(1Z M8RXXYT;NR$\>1L:PU?!EPOW!P4U['U.=(IX!FF^^J[& !R)+ JZJ R[BBJ?V\4A+2Q-1O,#HQ=JYFYI\#-256Y<5X4-QA73"W#CVT> S*U? M406^9?INI5;HS!U?KE&GOF7TFDU8\]'VS2'ZQN$#\'@,#8(%^E.;0X.O;: \ M_W1YV_P77+SJ?[^^^/]02P,$% @ PHN26)'-DS5C;CMLV$'TOT']@]2[+LI.V-E8;I-UNL( W"39I ML4!1!+1$VT0EDB6IV(NB_YXA)>KBE1S)[D/>2,^9.6=X&0]U]>J0I>@SD8IR M%GGA9.HAPF*>4+:-O%QO_)^]5]???W?U@^^_(8Q(K$F"UD_HYO;N+7K\Y6&% M[IC2F,4$W? XSPC3R$<[K<4R"/;[_2394*9XFFL@4).89P'8_R@(T<-\,H4I MC,*%_UI(FOJSZ>P%^G,Z6X8_+6?SO]"_K^__\WTC0<4[DF&DL=P2_19G1 D< MD\AKD&4DH3%.A>2"2$V)TC)7VK*:N-,7X0SR2XF1> M8T4<_/ ,7T8/%XM%8*T5% +1$Z%IN6=-?*(KAR;X95 8:Q4GXCZN&B)RY6\Q M%A5\@]7:0DN#6;BY \<\9UH^M24H$D^V_'-0&ML.N91P4OL\2FO+)2&T&PV& M%I 5H> M.;34@3DP9N,S]:>A/PL]4QHP8UQC4V+L3 C*-MP,S:58FEP^@A M;+L&OW*HCN_Q%NX*A36KIU7XA$")HY8\A'L.]:Q1"2T>&8>KX!CM N2*)._8 MM1W#[BCPM+F8RU1ZE9 NCSK@,#PD&^=I/T'06K,JA*M&#V2#;*U9FHV(/$4S MD9I"8G_;2;*)/"B>OJN*GR"C"6RN0YC )RJ(7?/C12AY78CR>)XNA4&]HXU* M&ER>#ZSWV'S:6_1-99/B]=ALP(6DWUPB<*S')G)T$_[G=()&&0K:!0IRX5(C MUMG#]/U3%^W/BLEJ2+3CEQG3X!2;5ROYA#.1^<;'>3[I>&L3=] MJMEY_(V^:A!WA;>C\SB;_=D@TMJA&)Y'6_=Z@T@=W S.)*Q[P&&,#F]'@SF? MMY&VR#*R-=WFL#N<2MGR,A=Y88I'^.-%$@:6D :]OICZ=!,]5$XSRF]UD)'J M>EX[@XZ#@YO!X,/0]UZYH++:,.,%'+\SABEP#YF"O8IQ%OV%Q&?=OZZ'4J^" MKWG:N6IH*+^@6!&1=R_T.V&^#%&V?8^E9D2J'14K<4^R-9$>*CJXZFFW3'B& M*;O3)#,O# _A-3RZX'Q''KR]3(]GOEXL(23ERJ-Y+F(O(*'@@[7LA4K=/T%4$L#!!0 ( ,*+DEB! MB.G2;0$ ,$" 4 ;7!W+3(P,C0P-#$R7V-A;"YX;6R=D5]+PS 4Q=\% MOT.,SVGZ9Z K=F,ZE,$4F2B"^-"U=ULP34J2V@[QNYM$*TX4P;?DWM^YY^3F M9-Q5'#V#TDR*#$=!B!&(0I9,K#/P* MW9\NYF@FM,E% 6@JBZ8"81!!&V/JE-*V;8-RQ826O#'60 >%K*CMW[T;HD42 MA/9J3]&03&K%.(G#>( >PCB-CM(X>40OD\M70EP$SL33,M> ;&2A,_S%I%LJ M'DBUIG$8)K0'\3N9=IKMT&W2LQ&]OYS?%!NH: S($HH^T1NP#_-G!7]YN5K_8Y&;U!+ P04 M " #"BY)8N*%*',T% #@,@ % &UP=RTR,#(T,#0Q,E]D968N>&UL MU5MM;^HV&/T^:?\A8Y]#(+2W!5WN%:/M%5I?4,NVJTT3,HD!:XD=V:: IOWW MV3$IA-HAM'6K?&H(C^USGO-@^SCIYZ^K.'(>(66(X&ZM66_4'(@#$B(\Z]86 M?.J>U[Y^^?&'SS^Y[C>((04:. MZ\PY3SJ>MUPNZ^$484:B!1<#L'I 8D]\_[L:T+EOU1OBH[AJMMU>0E'D^@W_ MQ/FKX7>:9QV_];?S;^_F/]>5$"*$_YD !AT!&;-N;6>0U81&=4)GGM]HM+PL ML*8B.RN&C:-=OMMI=^*T(9ZK"T_34) M $^3>!"78XR0G]PLS)6WW*;OMIKU%0N?<(F8D#\-L]O!J:>^K,ET41+!>SAU M4J0=ODY@M\90G$2287IO3N&T6XN399KTQDG3E^/\W">B'H9@)N)D'[_=#W*< M8ABB $0))0FD'$'&Z8+Q5%D9[NTT]R0.0(,,RN9RM\TU<,0UQ+)FW1!.P2+B;PA.T_<;024Q0-@.TDW7KP*: M]N'&,)Y ^I8H\_V^!N)Y:=)4;!*XXQ"$,LV$DFA?.&NE43X)<]Y&<7 E]3H)EV6 PJ,_(HQ="))CX M+7DAI[66J@B(QMGR-,!30F.PH0$'',8LZS@"$QBEPXT/-1F+'#5:)YO4O!/@ M$9ALI3P,-@U70)O/-.S1/&110UG/FW(Z:I*>4A(?F;G-Z.0(#JH^.P'!7)3< M901EM*AQ.),7V^\CPF#8K8DB$^E:,$&%)+(W(/ 2&D(J]CHOEFX*V"1-!Z-< M:0#@NXIDQ.S M%!^]+OZ'Z'*16RI+**,:*"XM*]J8UO&M,*6R7$Z8/3IZ:5H5E&:B%.+6X1>J+\0CDM7T5@9M@7Y&(4UK./2/\KM@5Z M"OIT?WJ''=D04D1$_807HHX.;,=RL2GVDT;%TE],12_#F449^HBO>Q2"/@E- MV=\-44C;%4NZEH$^U^<6VP7>H:%H;$O]PCETW\ >$)H2F%!ZX M6/#[9"%^B>N"1;=$2T7,SEF&;7G*$3,H]G+K7%:Q$5@-0L$-39%Z$E7B=V-H MH\A8.M6PK-(A2@9];![D*F"],*20L@B4U[G0,E_<\='9&E[N2O(%H1J*;C,),QJ&'39><@ MI2I%".#./9M^0;7D# .HC]1&YGDUK_@=%G$/<)W&\P)N- MG^FIOC96@:^:;RRF8M#!IFM_(!$*D'Q0:""735K6,##D'Z; MWGU(H:P%*%:G] Q'OI-#[Z93XTQD;J!H5,T#EN!CD,6F0=]#-6!L >G1XCQK MIBA5S0Z69F40RJ93?X#!0DRIZZ8_&2%N?-5J/TQ!KIH'-+(P)-ZF'1]1(%\Y M?UC'$V):,G(Q"FS5;)Z>@B'?-JUVIOWE*I@#/(,%C_5TH0IZU]H6BD@U;5PQ(8,R&54O_UIR>DN.(_^%XLO_ M4$L#!!0 ( ,*+DE@_:]DZ/ < -E1 4 ;7!W+3(P,C0P-#$R7VQA M8BYX;6S-G%UOVS84AN\'[#]PWLT&3/Z0BVT)F@Y>DA;&G,1(W*U84!2R1-O$ M)-&@Z-K&L/\^DI(GZO-?;;K==;X'""/L;RCJ(NBX.>NS\GW&'X'[8[;-# M]FEP9HW6!/F6W;??@,>^?3[XY=P>?@;_CF[^LRQNP4?A/W,G@H!9#J.+3J:3 MW9SX74R6/;O?'_9282=6GN\BE%-OAZEVT/MT,WEP5S!P+)2,XQ#%FY'%#<[. MSGKB+)-&Z#P2\1/L.E1,8JTOH%3P(RN56?PK:V!;PT%W%WD=/@<$^_ >+H#H M_ISNU_"B$Z%@[7/;XKL5@0NY!Y^0'H_OA7#)T\C;/^/M#W[F[7^??#UQYM#O M *[\>#]6#NKXS_*< MC=3E]A8^;WZ?XK3-*[L/PN?-:R;RE&YIV>G1DYF;19]_GK#^<\[@CL+0@U[J MC4=6W#E%P^*.*YK$;JXQG]]Z,2F/,V*-B88BZ':7^&O/@X@U: _Y![[2#,40 MV<&72\P6P=$\HL1Q:=J2\"[:_R+1/ TOYX; "&^("X\:6CQA^5Z=N:Q7MC@Q M!5^=86A]?.B\$^?!8ZKX_#9N[6!N1/*SY1 W[8E]K'&7*'HN9BOCFEHYHPN" M ^7L)%UBY4!Z;:4RK4/&X0*30"S*,V?^=!T4LJJ6:TIPA=]BK@\E5D8+'H7: M6-[KICN+0-U<'TW#PHGFPG5$:(P#]&G$CYZ88 >,/5Z$(H_?.J]#BBB"T6B' M(@D3U7(-3-3X+5__3U*0:MG]@*F-,-%DNE,FFLRU5B:N<."@\ @JT@"#7!P\ M-R0CUK\J-O+37D='?LZ;\!&LMV)CV7\SL$7^V1=?;M;T;LUWM&RO.V4U-=O= M1BNTGJQO8#"'1 )!HR@-)#1S7\3A9CH#AQ"0B0&3*7B,PXQ0<40R4C1T9\)+ M%BZQ9&G)2#>;"3U5$JO2X9C"0+8JUH>8JY:ROIM53#P"B)#75#:5YK^F="I- M?@N8C%B?'N_WO>\L%5P4-)I *#HK9OYP'G!!,:J>6E^C:?N=]E6HL=AKP\X +]%/V(GO:'@U(LQ1I&8XEF-!-?ROSR\^8P?(X[WM"MY:9+,>UP&B$VCX2:MLX MU/:Q6,RV^/5 ?0KWIJ&VCX':U@4UKY7OR QO94^I*]4F@,ZYK0-";%8P 5QN M&.63^38"<9D1)<)E0-H&>(HCZOA_HW7%3K\JP 3&1<]U1,1ZP (,/19HT[T1 MI*74**F6(M,VV ^4[0COR)3@KRAT&Z%="C$!=]EW'2 B@M_QTAC#@+

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end XML 22 d804873d8k_htm.xml IDEA: XBRL DOCUMENT 0001287865 2024-04-12 2024-04-12 0001287865 mpw:MptOperatingPartnershipLpMember 2024-04-12 2024-04-12 MEDICAL PROPERTIES TRUST INC false 0001287865 0001524607 AL AL 8-K 2024-04-12 MPT OPERATING PARTNERSHIP, L.P. 001-32559 333-177186 MD 20-0191742 DE 20-0242069 1000 Urban Center Drive 1000 Urban Center Drive Suite 501 Suite 501 Birmingham Birmingham 35242 35242 205 205 969-3755 969-3755 false false false false Common Stock, par value $0.001 per share, of Medical Properties Trust, Inc. MPW NYSE false false